2023

Peer-reviewed Publications

  1. Barbour W, Wolff E, Puar P, Hibino M, Bakbak E, Krishnaraj A, Verma R, Verma M, Quan A, Yan AT, Connelly KA, Teoh H, Mazer CD, Verma S. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian Individuals: insights from the EMPA-HEART CardioLink-6 clinical trial. BMC Cardiovasc Disord. 2023 Nov 15;23(1):557.
  2. Bakbak E, Verma S, Krishnaraj A, Quan A, Wang C-H, Pan Y, Puar P, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1210-H1222.
  3. Hibino M, Peterson MD, Tachibana R, Chu MWA, Bozinovski J, Dagenais F, Quan A, Papa FdV, Dickson J, Teoh H, Alli A, Hare GMT, Smith EE, Verma S, Mazer CD. Association of cerebral oximetry with brain ischemic lesions and functional outcomes in arch repair. Ann Thorac Surg. 2023 Oct;116(4):854-858.
  4. Hibino M, Pandey AK, Verma S, Puar P, Teoh H, Quan A, Verma R, Yau TM, Bisleri G, Yanagawa B, Mazer CD, Verma A, Ha ACT. Wearable cardiac rhythm monitoring device for detection of post-operative atrial fibrillation. Ann Thorac Surg. 2023 Oct;116(4):854-858.
  5. Mistry N, Verma S, Puar P, Verma R, Teoh H, Quan A, Yan AT, Wang C-H, Connelly KA, Mazer CD, EMPA-HEART investigators. A Patient-Level Pooled Analysis of Two Empagliflozin Trials on Left Ventricular Remodeling. J Card Fail. 2023 Aug;29(8):1218-1221.
  6. Hibino M, Dhingra NK, Verma S, Chan V, Quan A, Gregory AJ, Chu MWA, Ong G, Teoh H, Mazer CD, Tsang W, Messika-Zeitoun D, Leong-Poi H, Connelly KA; CAMRA Trial CardioLink-2 Collaborators. Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trial. J Thorac Cardiovasc Surg. 2023 Jul;166(1):74-83.
  7. Puar P, Hibino M, Mazer CD, Yan AT, Pandey AK, Quan A, Teoh H, Hess DA, Verma R, Connelly KA, Verma S. Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin. Cardiovasc Diabetol. 2023 Jun 28;22(1):152.
  8. Puar P, Ahmed S, Hibino M, Pasricha A, Pandey A, Bari A, Verma R, Quan A, Yan AT, Connelly KA, Teoh H, Mazer CD, Verma S. The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease. Diabetes Obes Metab. 2023 Sep;25(9):2765-2769.
  9. Verma R, Moroney M, Hibino M, Mazer CD, Connelly KA, Yan AT, Quan A, Teoh H, Verma S, Puar P. Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling. ESC Heart Fail. 2023 Jun;10(3):2127-2133.
  10. Moroney M, Verma R, Hibino M, Mazer CD, Connelly KA, Yan AT, Quan A, Teoh H, Verma S, Puar P. Impact of diabetes duration on left ventricular mass regression with empagliflozin. ESC Heart Fail. 2023 Jun;10(3):2134-2140.
  11. Puar P, Mistry N, Connelly KA, Yan AT, Quan A, Teoh H, Pan Y, Verma R, Hess DA, Verma S, Mazer CD. IGFBP7 and Left ventricular mass regression: A sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial. ESC Heart Fail. 2023 Jun;10(3):2113-2119.
  12. Rumman RK, Verma S, Chan V, Mazer CD, Quan A, Hibino M, de Varennes BE, Chu MWA, Latter DA, Teoh H, Yanagawa B, Leong-Poi H, Connelly KA. Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation. Heart 2023;109:866–873.
  13. Hibino M, Pandey A, Chan V, Mazer CD, Rumman R, Dhingra NK, Bonneau C, Verma R, Yokoyama Y, Quan A, Teoh H, Cheema A, de Varennes BE, Yanagawa B, Leong-Poi H, Connelly KA, Bisleri G, Verma S. Risk Factors for Post-Repair Elevated Mitral Gradient: A Post-Hoc Analysis of a Randomized Trial. Ann Thorac Surg. 2023 Feb;115(2):437-443.
  14. Connelly KA, Mazer CD, Puar P, Teoh H, Wang C-H, Mason T, Akhavein F, Chang C-W, Liu M-H, Yang N-I, Chen W-S, Juan Y-H, Opingari E, Salyani Y, Barbour W, Pasricha A, Ahmed S, Kosmopoulos A, Verma R, Moroney M, Bakbak E, Krishnaraj A, Bhatt DL, Butler J, Kosiborod MN, Lam CSP, Hess DA, Coelho-Filho OR, Lafreniere-Roula M, Thorpe KE, Quan A, Leiter LA, Yan AT, Verma S. Empagliflozin and left ventricular remodeling in people without diabetes. Primary results of the EMPA-HEART 2 CardioLink-7 randomized clinical trial. Circulation. 2023 Jan 24;147(4):284-295.
  15. Chen C-H, Peterson MD, Mazer CD, Hibino M, Beaudin A, Chu MWA, Dagenais F, Teoh H, Quan A, Dickson J, Verma S, Smith EE. Acute infarcts on brain MRI following aortic arch repair with circulatory arrest: Insights from the ACE CardioLink-3 randomized trial. Stroke. 2023 Jan;54(1):67-77.

Conference Abstracts

  1. Rumman RK, Verma S, Chan V, Fottinger A, Quan A, Hibino M, de Varennes BE, Chu MWA, Teoh H, Yanagawa B, Bisleri G, Leong-Poi H, Mazer CD, Connelly KA. Comparison of myocardial mechanics post mitral valve repair with leaflet preservation vs. leaflet resection: A sub-analysis of the randomized CAMRA CardioLink-2 trial.
    American Heart Association Scientific Sessions, Philadelphia, PA, USA, November 11-13, 2023.
    Circulation. 2023;148:A16308.
  2. Yang N-I, Wang C-H, Mazer CD, Verma S. Effects of empagliflozin on fatty acid binding protein 4 and body composition in patients without diabetes but with risk factors for adverse cardiac remodeling from the EMPA-HEART 2 CardioLink-7 randomized clinical trial.
    American Heart Association Scientific Sessions, Philadelphia, PA, USA, November 11-13, 2023
    Circulation. 2023;148:A15785.
  3. Krishnaraj A, Bakbak E, Firoz IN, Pan Y, Bari B, Bakbak AI, Padanilathu Kunjummar S, Quan A, Teoh H, Hess DA, Verma S. South Asian individuals with type 2 diabetes have less vascular regeneration cell content.
    Vascular 2023, Montreal, Quebec, Canada, October 25-29, 2023
    Can J Cardiol. 2023; 39 (10 Suppl): S233.
  4. Bakbak E, Verma S, Krishnaraj A, Quan A, Puar P, Wang C-H, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Empagliflozin improves vascular regenerative cell content in people without diabetes.
    Vascular 2023, Montreal, Quebec, Canada, October 25-29, 2023.
    Can J Cardiol. 2023; 39 (10 Suppl): S195-S196.
  5. Krishnaraj A, Park B, Bakbak E, Pan Y, Quan A, Teoh H, Verma S, Hess DA. GLP-1RA therapy is associated with higher vascular regenerative cell content and lower inflammatory burden in people with type 2 diabetes.
    Vascular 2023, Montreal, Quebec, Canada, October 25-29, 2023.
    Can J Cardiol. 2023; 39 (10 Suppl): S201-S202.
  6. Krishnaraj A, Bakbak E, Firoz IN, Pan Y, Terenzi D, Bari B, Bakbak AI, Padanilathu Kunjummar S, Rotstein OD, Quan A, Teoh H, Hess DA, Verma S. South Asian adults with ASCVD exhibit a reduction in circulating vascular regenerative cell content compared to White European adults: a sub-analysis of the ORIGINS-RCE CardioLink-13 study.
    ESC Congress 2023, 25th-28th August 2023, Amsterdam, Netherlands
    Eur Heart J. 2023; 44 (Supplement_2):3046
  7. Bakbak E, Krishnaraj A, Quan A, Terenzi DC, Puar P, Pan Y, Bakbak A, Bari B, Terenzi K, Rotstein OD, Teoh, H, Leiter, LA, Bhatt LA, Hess DA, Verma S. Glomerular filtration rate predicts pro-vascular progenitor cell depletion: Insights from the IPE-PREVENTION and ORIGINS-RCE studies.
    ESC Congress 2023, 25th-28th August 2023, Amsterdam, Netherlands
    Eur Heart J. 2023; 44 (Supplement_2):274.
  8. Krishnaraj A, Park B, Bakbak E, Pan Y, Quan A, Teoh H, Hess DA, Verma S. GLP-1RA therapy increases circulating vascular regenerative cell content and decreases inflammatory burden in people with T2D.
    83rd Scientific Sessions of the American Diabetes Association, June 2023, San Diego, CA, USA.
    Diabetes 2023;72(Supplement_1):792-P.
  9. Hibino M, Peterson MD, Tachibana R, Chu MWA, Bozinovski J, Dagenais F, Quan A, Dickson J, Papa F, Teoh H, Smith EE, Verma S, Mazer CD. Association of cerebral oximetry with brain lesions and neurological outcomes following aortic arch repair with unilateral cerebral perfusion: A sub-analysis of the ACE CardioLink-3 trial.
    Annual Meeting of the American Association for Thoracic Surgeons, Los Angeles, California, USA, May 6-9, 2023.
  10. Hibino M, Verma R, Chan V, Mazer CD, Quan A, Teoh H, Yanagawa B, Bisleri G, Connelly KA, Verma S. The impact of preoperative left ventricular systolic dysfunction on reverse remodelling following mitral repair: insights from CAMRA CardioLink-2 randomized trial. The Mitral Conclave, May 4-5, 2023, New York, NY, USA.
  11. Krishnaraj A, Bakbak E, Firoz I, Pan Y, Quan A, Teoh H, Hess D, Verma S.Regenerative cell exhaustion and cardiovascular risk in South Asians: A pilot study.
    Annual Scientific Session of the American College of Cardiology, March 4-6, 2023, New Orleans, Louisiana, USA.
    J Am Coll Cardiol. 2023; 81 (8 Supplement A):1205.
  12. Verma R, Moroney M, Hibino M, Mazer CD, Connelly KA, Yan AT, Quan A, Teoh H, Verma S, Puar P. Baseline neutrophil to lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodeling.
    Annual Scientific Session of the American College of Cardiology, March 4-6, 2023, New Orleans, Louisiana, USA.
    J Am Coll Cardiol. 2023; 81 (8 Supplement A):292
  13. Bakbak E, Puar P, Krishnaraj A, Terenzi D, Mason T, Quan A, Teoh H, Yan AT, Connelly KA, Mazer CD, Hess DA, Verma S. Empagliflozin reduced circulating pro-inflammatory precursor cell content in people without diabetes: A substudy of the EMPA-HEART 2 CardioLink-7 trial.
    Annual Scientific Session of the American College of Cardiology, March 4-6, 2023, New Orleans, Louisiana, USA.
    J Am Coll Cardiol. 2023; 81 (8 Supplement A):2040.
  14. Moroney M, Verma R, Hibino M, Mazer CD, Connelly KA, Yan AT, Quan A, Teoh H, Verma S, Puar P. Impact of diabetes duration on left ventricular mass regression with empagliflozin.
    Annual Scientific Session of the American College of Cardiology, March 4-6, 2023, New Orleans, Louisiana, USA.
    J Am Coll Cardiol. 2023; 81 (8 Supplement A):289.
  15. Puar P, Hibino M, Ahmed S, Pasricha A, Pandey A, Bari A, Verma R, Quan A, Teoh H, Connelly KA, Yan AT, Mazer CD, Verma S. Association between anthropometric measures of obesity and left ventricular reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease: a sub-analysis of the EMPA-HEART CardioLink-6 trial.
    Annual Scientific Session of the American College of Cardiology, March 4-6, 2023, New Orleans, Louisiana, USA.
    J Am Coll Cardiol. 2023; 81 (8 Supplement A):433.
© 2024 CardioLink Canada. All rights reserved